These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34364965)

  • 1. Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: A systematic review of preclinical and clinical evidence.
    Leta V; Ray Chaudhuri K; Milner O; Chung-Faye G; Metta V; Pariante CM; Borsini A
    Brain Behav Immun; 2021 Nov; 98():59-73. PubMed ID: 34364965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.
    Raj K; Singh S; Chib S; Mallan S
    Curr Pharm Des; 2022; 28(37):3049-3067. PubMed ID: 36200207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotics and the Treatment of Parkinson's Disease: An Update.
    Mirzaei H; Sedighi S; Kouchaki E; Barati E; Dadgostar E; Aschner M; Tamtaji OR
    Cell Mol Neurobiol; 2022 Nov; 42(8):2449-2457. PubMed ID: 34283340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson's disease.
    Martini S; Marino F; Magistrelli L; Contaldi E; Cosentino M; Comi C
    Pilot Feasibility Stud; 2023 May; 9(1):77. PubMed ID: 37158925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics May Have Beneficial Effects in Parkinson's Disease:
    Magistrelli L; Amoruso A; Mogna L; Graziano T; Cantello R; Pane M; Comi C
    Front Immunol; 2019; 10():969. PubMed ID: 31134068
    [No Abstract]   [Full Text] [Related]  

  • 6. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity.
    Srivastav S; Neupane S; Bhurtel S; Katila N; Maharjan S; Choi H; Hong JT; Choi DY
    J Nutr Biochem; 2019 Jul; 69():73-86. PubMed ID: 31063918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment.
    Salim S; Ahmad F; Banu A; Mohammad F
    J Adv Res; 2023 Aug; 50():83-105. PubMed ID: 36332796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson's Disease.
    Hsieh TH; Kuo CW; Hsieh KH; Shieh MJ; Peng CW; Chen YC; Chang YL; Huang YZ; Chen CC; Chang PK; Chen KY; Chen HY
    Brain Sci; 2020 Apr; 10(4):. PubMed ID: 32244769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson's disease.
    Chu C; Yu L; Li Y; Guo H; Zhai Q; Chen W; Tian F
    Food Funct; 2023 Apr; 14(8):3406-3422. PubMed ID: 36974511
    [No Abstract]   [Full Text] [Related]  

  • 10. Probiotics for Parkinson's disease: Current evidence and future directions.
    Tan AH; Hor JW; Chong CW; Lim SY
    JGH Open; 2021 Apr; 5(4):414-419. PubMed ID: 33860090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease.
    Zhang W; Ye Y; Song J; Sang T; Xia T; Xie L; Qiu X; Zeng Q; Luo X
    J Integr Neurosci; 2023 Oct; 22(6):157. PubMed ID: 38176929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway.
    Sun J; Li H; Jin Y; Yu J; Mao S; Su KP; Ling Z; Liu J
    Brain Behav Immun; 2021 Jan; 91():703-715. PubMed ID: 33148438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease: Are gut microbes involved?
    Omotosho AO; Tajudeen YA; Oladipo HJ; Yusuff SI; AbdulKadir M; Muili AO; Egbewande OM; Yusuf RO; Faniran ZO; Afolabi AO; El-Sherbini MS
    Brain Behav; 2023 Aug; 13(8):e3130. PubMed ID: 37340511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.
    Kalinderi K; Papaliagkas V; Fidani L
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotic
    Pan S; Wei H; Yuan S; Kong Y; Yang H; Zhang Y; Cui X; Chen W; Liu J; Zhang Y
    Front Cell Infect Microbiol; 2022; 12():1022879. PubMed ID: 36439235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of pluripotent stem cell-derived dopaminergic progenitors in Parkinson's disease: a systematic review protocol.
    Karimi A; Elmi M; Shiri Z; Baharvand H
    Syst Rev; 2021 Jun; 10(1):188. PubMed ID: 34172098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.